Cardiac characteristics and long-term outcome in Andersen-Tawil syndrome patients related to KCNJ2 mutation

Europace

Volumn 15, Issue 12, 2013, Pages 1805-1811

  Delannoy, Eric ^a   Sacher, Frédéric ^b   Maury, Philippe ^c   Mabo, Philippe ^d   Mansourati, Jacques ^e   Magnin, Isabelle ^f   Camous, Jean Pierre ^g   Tournant, Guillaume ^h   Rendu, Eric ^a   Kyndt, Florence ^a,i   Haïssaguerre, Michel ^b   Bézieau, Stéphane ^a   Guyomarch, Béatrice ^a,i   Le Marec, Hervé ^a,i   Fressart, Véronique ^j   Denjoy, Isabelle ^k,l   Probst, Vincent ^a,i  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e BREST UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

^g UNIVERSITY HOSPITAL OF NICE   (France)

^h MONTPELLIER UNIVERSITY HOSPITAL   (France)

ⁱ L INSTITUT DU THORAX   (France)

^j CNRS UMR 6291 l'Institut du Thorax ^*  (France)

^k BICHAT HOSPITAL   (France)

^l HÔPITAL ROBERT DEBRÉ   (France)

more..

Author keywords

Andersen Tawil; Follow up; Prognosis; Ventricular arrhythmias

Indexed keywords

ACETAZOLAMIDE; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIBENZOLINE; FLECAINIDE; GENOMIC DNA; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; SPIRONOLACTONE;

ADULT; ANDERSEN SYNDROME; ARTICLE; CATHETER ABLATION; CLINICAL ARTICLE; CONTROLLED STUDY; FAINTNESS; FEMALE; FOLLOW UP; GENE; GENE MUTATION; HEART ARREST; HEART EJECTION FRACTION; HEART VENTRICLE BIGEMINY; HEART VENTRICLE EXTRASYSTOLE; HETEROZYGOTE; HOLTER MONITORING; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; KCNJ2 GENE; MALE; OUTCOME ASSESSMENT; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; QT INTERVAL; RESUSCITATION; RETROSPECTIVE STUDY; TORSADE DES POINTES;

ANDERSEN-TAWIL; FOLLOW-UP; PROGNOSIS; VENTRICULAR ARRHYTHMIAS;

ADOLESCENT; ADULT; AGED; ANDERSEN SYNDROME; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; ELECTROCARDIOGRAPHY; FEMALE; FRANCE; GENETIC PREDISPOSITION TO DISEASE; HEART ARREST; HUMANS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PROGNOSIS; RETROSPECTIVE STUDIES; SYNCOPE; TIME FACTORS; YOUNG ADULT;

EID: 84887999360     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut160     Document Type: Article

References (25)

1. Andersen ED, Krasilnikoff PA, Overvad H. Intermittent muscular weakness, extrasystoles, and multiple developmental anomalies. A new syndrome Acta Paediatr Scand 1971;60:559-64.
2. Plaster NM, Tawil R, Tristani-Firouzi M, Canún S, Bendahhou S, Tsunoda A et al. Mutationsin Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001;105:511-9.
3. Donaldson MR, Jensen JL, Tristani-Firouzi M, Tawil R, Bendahhou S, SuarezWA et al. PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome. Neurology 2003;60:1811-6.
4. Tristani-Firouzi M, Jensen JL, Donaldson MR, Sansone V, Meola G, Hahn A et al. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest 2002;110:381-8.
5. Smith AH, Fish FA, Kannankeril PJ. Andersen-Tawil syndrome. Indian Pacing Electrophysiol J 2006;6:32-43.
6. Junker J, HaverkampW, Schulze-Bahr E, Eckardt L, PaulusW, Kiefer R. Amiodarone and acetazolamide for the treatment of genetically confirmed severe Andersen syndrome. Neurology 2002;59:466.
7. Sumitomo N, ShimizuW, Taniguchi K, Hiraoka M. Calcium channel blocker and adenosine triphosphate terminate bidirectional ventricular tachycardia in a patient with Andersen-Tawil syndrome. Heart Rhythm 2008;5:498-9.
8. Bökenkamp R, Wilde AA, Schalij MJ, Blom NA. Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome. Heart Rhythm 2007;4:508-11.
9. Lopes CM, Zhang H, Rohacs T, Jin T, Yang J, Logothetis DE. Alterations in conserved Kirchannel-PIP2 interactions underlie channelopathies. Neuron 2002;34:933-44.
10. Hibino H, InanobeA, Furutani K, Murakami S, Findlay I, Kurachi Y. Inwardly rectifying potassium channels: their structure, function, and physiological roles. Physiol Rev 2010;90:291-366.
11. Zhang L, Benson DW, Tristani-Firouzi M, Ptacek LJ, Tawil R, Schwartz PJ et al. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype. Circulation 2005;111:2720-6.
12. Yoon G, Oberoi S, Tristani-Firouzi M, Etheridge SP, Quitania L, Kramer JH et al. Andersen-Tawil syndrome: prospective cohort analysis and expansion of the phenotype. Am J Med Genet A 2006;140:312-21.
13. Airey KJ, Etheridge SP,Tawil R, Tristani-Firouzi M. Resuscitated sudden cardiac death in Andersen-Tawil syndrome. Heart Rhythm 2009;6:1814-7.
14. Peters S, Schulze-Bahr E, Etheridge SP, Tristani-Firouzi M. Sudden cardiac death in Andersen-Tawil syndrome. Europace 2007;9:162-6.
15. Pellizzón OA, Kalaizich L, Ptácek LJ, Tristani-Firouzi M, GonzalezMDet al. Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome. J Cardiovasc Electrophysiol 2008; 19:95-7.
16. Erdogan O, Aksoy A, Turgut N, Durusoy E, Samsa M, Altun A. Oral verapamil effectively suppressed complex ventricular arrhythmias and unmasked U waves in a patient with Andersen-Tawil syndrome. J Electrocardiol 2008;41:325-8.
17. Kannankeril PJ, Roden DM, Fish FA. Suppression of bidirectional ventricular tachycardia and unmasking of prolonged QT interval with verapamil in Andersen's syndrome. J Cardiovasc Electrophysiol 2004;15:119.
18. Hässaguerre M, Extramiana F, Hocini M, Cauchemez B, Jäs P, Cabrera JA. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation 2003;108:925-8.
19. Sanders P, Hsu LF, Hocini M, Jäs P, Takahashi Y, RotterMet al. Mapping and ablation of ventricular fibrillation. Minerva Cardioangiol 2004;52:171-81.
20. Chun TUH, Epstein MR, DickMII, Andelfinger G, Ballester L, VanoyeCGet al. Polymorphic ventricular tachycardia and KCNJ2 mutations. Heart Rhythm 2004; 1:235-41.
21. Tristani-Firouzi M, Etheridge SP. Kir 2.1 channelopathies: the Andersen-Tawil syndrome. Pflugers Arch 2010;460:289-94.
22. Wang Z, Yue L, White M, Pelletier G, Nattel S. Differential distribution of inward rectifier potassium channel transcripts in human atrium versus ventricle. Circulation 1998;98:2422-8.
23. Postema PG, Ritsema van Eck HJ, Opthof T, van Herpen G, van Dessel PFHM, Priori SG et al. IK1 modulates the U-wave: insights in a100-year-old enigma. Heart Rhythm 2009;6:393-400.
24. Morita H, Zipes DP, Morita ST,Wu J. Mechanism of U wave and polymorphic ventricular tachycardia in a canine tissue model of Andersen-Tawil syndrome. Cardiovasc Res 2007;75:510-8.
25. Tsuboi M, Antzelevitch C. Cellular basis for electrocardiographic and arrhythmic manifestations of Andersen-Tawil syndrome (LQT7). Heart Rhythm 2006;3:328-35.